ProCE Banner Activity

Long-term Ixazomib Maintenance in ASCT-Ineligible Patients With Newly Diagnosed MM: Pooled Analysis of 4 Phase I/II Trials

Slideset Download
Conference Coverage
Among patients with newly diagnosed MM not undergoing ASCT, ixazomib-based induction followed by ixazomib maintenance therapy was associated with an ORR of 94%, including a CR rate of 35%.

Released: December 18, 2017

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

AstraZeneca

Celgene

Genentech TEXT Only

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Pharmacyclics Inc

Seagen

Takeda Oncology